Učitavanje...

Aromatase inhibition in advanced prostatic cancer: preliminary communication.

We report the results of the first use of a steroidal aromatase inhibitor, 4-hydroxyandrostenedione (4-OHA, CGP 32349), in the palliation of patients with advanced, hormone resistant, prostatic cancer. Twelve of 19 patients (63%), who had relapsed following castration and other therapies, gained sig...

Cijeli opis

Spremljeno u:
Bibliografski detalji
Glavni autori: Shearer, R. J., Davies, J. H., Dowsett, M., Malone, P. R., Hedley, A., Cunningham, D., Coombes, R. C.
Format: Artigo
Jezik:Inglês
Izdano: Nature Publishing Group 1990
Teme:
Online pristup:https://ncbi.nlm.nih.gov/pmc/articles/PMC1971817/
https://ncbi.nlm.nih.gov/pubmed/2201397
Oznake: Dodaj oznaku
Bez oznaka, Budi prvi tko označuje ovaj zapis!